TR200200133T2 - GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. - Google Patents

GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Info

Publication number
TR200200133T2
TR200200133T2 TR2002/00133T TR200200133T TR200200133T2 TR 200200133 T2 TR200200133 T2 TR 200200133T2 TR 2002/00133 T TR2002/00133 T TR 2002/00133T TR 200200133 T TR200200133 T TR 200200133T TR 200200133 T2 TR200200133 T2 TR 200200133T2
Authority
TR
Turkey
Prior art keywords
gdf
methods
analogs
homologous
nucleic acid
Prior art date
Application number
TR2002/00133T
Other languages
English (en)
Inventor
Halkier Torben
Mouritsen S�ren
Klysner Steen
Original Assignee
Pharmexa A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa A/S filed Critical Pharmexa A/S
Publication of TR200200133T2 publication Critical patent/TR200200133T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of Eletrric Generators (AREA)
  • Debugging And Monitoring (AREA)

Abstract

Büyüme Farklilasmasi Faktörü 8'e (GDF-8, miyostatin) karsi bagisiklik kazandirarak kas kütlesinin arttirilmasi için yeni yöntemler açiklanmistir. Bagisiklik kazandirma tercihen homolog GDF-8'e karsi antikor üretimini baslatabilen GDF-8 analoglarinin uygulanmasiyla gerçeklestirilir. Immünojen olarak özellikle tercih edilen, homolog GDF-8'in üçüncül yapisini büyük ölçüde korurken, bir veya birkaç yabanci, immünodominant ve ayrimsiz T-hücresi epitopunun sokulmasiyla modifiye edilmis olan homolog GDF-8'dir. Yine, GDF-8'e karsi nükleik asit asilama ve canli asilari kullanarak yapilan asilamanin yani sira, asilama için faydali yöntemler ve vasitalar da açiklanmistir. Bu yöntemler ve vasitalar, faydali immünojenik GDF-8 analoglarinin tanimlanmasi için yöntemleri, analoglarin ve farmasötik formülasyonlarin hazirlanmasi için yöntemleri,ayrica nükleik asit parçalarini, vektörleri, transforme edilmis hücreleri, polipeptitleri ve farmasötik formülasyonlari içerir.
TR2002/00133T 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. TR200200133T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26

Publications (1)

Publication Number Publication Date
TR200200133T2 true TR200200133T2 (tr) 2002-05-21

Family

ID=26065065

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2002/00133T TR200200133T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
TR2004/00621T TR200400621T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2004/00621T TR200400621T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Country Status (21)

Country Link
US (2) US7056512B1 (tr)
EP (1) EP1200119A2 (tr)
JP (1) JP2003506325A (tr)
KR (1) KR100750695B1 (tr)
CN (1) CN1384757A (tr)
AU (1) AU778470B2 (tr)
CA (1) CA2379852A1 (tr)
EA (1) EA005248B1 (tr)
EE (1) EE200200025A (tr)
HK (1) HK1048937A1 (tr)
HR (1) HRP20010900A2 (tr)
HU (1) HUP0201861A3 (tr)
IL (1) IL146845A0 (tr)
MX (1) MXPA01013232A (tr)
NO (1) NO20016252L (tr)
NZ (1) NZ517058A (tr)
PL (1) PL353855A1 (tr)
SK (1) SK722002A3 (tr)
TR (2) TR200200133T2 (tr)
WO (1) WO2001005820A2 (tr)
ZA (1) ZA200109901B (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
EP2272864A3 (en) * 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
CN1829532A (zh) 2003-06-02 2006-09-06 惠氏公司 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
SG153874A1 (en) * 2003-12-31 2009-07-29 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
ATE552272T1 (de) 2004-09-30 2012-04-15 Orico Ltd Myostatin-isoform
CN101379086B (zh) 2005-08-19 2013-07-17 惠氏公司 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途
JP2009545313A (ja) 2006-08-03 2009-12-24 オリコ・リミテッド ミオスタチンアンタゴニスト
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
US8501713B2 (en) 2007-08-03 2013-08-06 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2013003983A1 (zh) * 2011-07-06 2013-01-10 湖北省农业科学院畜牧兽医研究所 猪肌抑素基因座位及其应用
LT2780368T (lt) 2011-11-14 2018-03-12 Regeneron Pharmaceuticals, Inc. Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
EP3711771A1 (en) 2012-08-01 2020-09-23 Ikaika Therapeutics, LLC Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
EA201792298A1 (ru) 2015-04-15 2018-04-30 Регенерон Фармасьютикалз, Инк. Способы увеличения силы и функциональности с помощью ингибиторов gdf8
KR20200128125A (ko) 2018-03-01 2020-11-11 리제너론 파아마슈티컬스, 인크. 신체 조성을 변경하기 위한 방법
US20220143136A1 (en) 2018-12-21 2022-05-12 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
AR012427A1 (es) 1997-04-15 2000-10-18 Pharmexa As Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn
EP1002068B1 (en) * 1997-07-14 2009-09-09 University of Liège Mutations in the myostatin gene cause double-muscling in mammals
CA2315256A1 (en) * 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
PL353855A1 (en) 2003-12-01
CA2379852A1 (en) 2001-01-25
HRP20010900A2 (en) 2003-08-31
HUP0201861A3 (en) 2004-07-28
MXPA01013232A (es) 2005-05-24
SK722002A3 (en) 2003-02-04
HUP0201861A2 (en) 2002-09-28
TR200400621T2 (tr) 2004-08-23
EA200200182A1 (ru) 2002-06-27
KR20020026544A (ko) 2002-04-10
NZ517058A (en) 2004-04-30
EA005248B1 (ru) 2004-12-30
CN1384757A (zh) 2002-12-11
US7070784B1 (en) 2006-07-04
KR100750695B1 (ko) 2007-08-22
WO2001005820A2 (en) 2001-01-25
JP2003506325A (ja) 2003-02-18
HK1048937A1 (zh) 2003-04-25
NO20016252L (no) 2002-03-15
AU778470B2 (en) 2004-12-09
EE200200025A (et) 2003-04-15
AU5967500A (en) 2001-02-05
US7056512B1 (en) 2006-06-06
WO2001005820A3 (en) 2001-07-19
NO20016252D0 (no) 2001-12-19
EP1200119A2 (en) 2002-05-02
ZA200109901B (en) 2003-05-28
IL146845A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
TR200200133T2 (tr) GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
NO20023961D0 (no) Ny fremgangsmåte for nedregulering av amyloid
MXPA02007796A (es) Metodo novedoso para la disminucion de cuerpos amiloides.
JP4880184B2 (ja) ワクチン
US5500366A (en) Polynucleotide encoding T-cell epitopes of the protein TraT
CA2457140A1 (en) Beta-amyloid-analogue - t-cell epitope vaccine
IL118579A (en) Immunogenic composition comprising an antigen and a lipoprotein
RU2010138815A (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
CA2325566A1 (en) Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
JP2007332149A (ja) マイコバクテリア感染症に対するワクチン
Migliorini et al. Malaria vaccine: immunization of mice with a synthetic T cell helper epitope alone leads to protective immunity
EP0475478B1 (en) Haemophilus paragallinarum vaccine
NO20051779L (no) Immunisering mot autologt ghrelin
JP3881514B2 (ja) クラミジア感染症に対するｄｎａ免疫化
Wiesmüller et al. The antibody response in BALB/c mice to the Plasmodium falciparum circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant.
NO20040431L (no) Ny fremgangsmate for nedregulering av amyloid
Menon et al. Mycobacterial ESAT-6 protein enhances mouse IFN-γ responses to Mycoplasma hyopneumoniae P71 protein
Todryk et al. Effect of route of immunisation and adjuvant on T and B cell epitope recognition within a streptococcal antigen
EP2632942A2 (en) Recombinant envelope protein of human immunodeficiency virus (hiv) and vaccine containing the same
YU87201A (sh) Postupak za nishodnu regulaciju gdf-8 aktivnosti
JP4815090B2 (ja) Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ外膜タンパク質およびワクチン接種におけるその使用
WO2007112702A2 (es) Composición farmacéutica que comprende la proteína nmb0938
ES2276673T3 (es) Fracciones de membranas bacterianas con efecto adyuvante.
JP2002538169A (ja) インフルエンザ菌に起因する疾患を防御するための、少なくとも３つの抗原を含む多成分系ワクチン
KR20180017554A (ko) 어류 바이러스성 출혈성 패혈증에 대한 예방 또는 치료용 dna 백신